60 Degrees Pharmaceuticals Inc (SXTP)

$1.95 +0.02 (1.04%)
Market Cap 2.24M
Revenue (ttm) 680,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,169.12%
Debt to Equity Ratio 0.00
Volume 64,300
Avg Vol 5,508,747
Day's Range N/A - N/A
Shares Out 1.06M
Stochastic %K 8%
Beta 3.01
Analysts Sell
Price Target $17.60

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidi...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
Goldwave9
Goldwave9 Mar. 21 at 5:17 PM
$SXTP give this a chance and I don't mean in hours or even in days. It's going to make big move but many of you will have moved on out of boredom
1 · Reply
ReversalTrack
ReversalTrack Mar. 20 at 4:38 PM
Something is brewing on ticker JAGU 🚨🚀 One of the most explosive signals is setting up on the daily. Uranium+Rare earth play with news . War changes everything especially energy. ⚛️ Uranium = energy independence + national security Don't sleep on ticker JAGU!! $SXTP $IPW $IBG $SRXH hot also.1
0 · Reply
ReversalTrack
ReversalTrack Mar. 18 at 10:39 PM
JAGU ✅ Starting to get found, massive potential on this! Make sure to put JAGU on your watchlist. Beaten down IPO now starting to reverse/news yesterday. JAGU uranium/rare earth play, hot sector right now, don't miss this gem! JAGU: ✅23M in cash ✅4$ IPO a month ago ✅No dilution filed ✅Positioned in a growing sector ✅Insiders shares are locked 6 months ✅Laguna salada project covers 230 000 hectares $IPW $SXTP $SRXH $GLD . hot.
1 · Reply
DARKP00L
DARKP00L Mar. 18 at 12:11 PM
$SXTP 08:10 on Mar. 18 2026 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification With FDA For Australian Chestnut Extract; Inks Deal To License Florida State University's Ownership Rights To New Capsule Formulation Methods For Australian Chestnut Extract #tradeideas
0 · Reply
Marty4172
Marty4172 Mar. 17 at 2:46 PM
$SXTP Up on crazy low volume today lfg
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 17 at 6:35 AM
$SXTP lost all gains in 3 days.. on low volume
0 · Reply
TheswingLifes
TheswingLifes Mar. 15 at 6:18 PM
$IPM 5m float, no dilution, great revenues, hot theme that is waiting to take off, whats there not to like, going to get sent, don't be left behind. $ISPC $SAFX $SXTP $CXAI Watching for continuation.
1 · Reply
focafoca99
focafoca99 Mar. 14 at 10:51 PM
$SXTP anything tied to H.C. Wainwright usually gets read through a financing lens first, and I dont think this is any different.
0 · Reply
speedom33
speedom33 Mar. 14 at 2:34 PM
$SXTP The SEC filing was about ATM status. The remaining is 565K which is equavalent to 240,000 shares if converted based on 2.39 closed price. The remaining is a update as of March 12 and may be lowered if more shares were sold through ATM on March 13. I think it is almost done.
0 · Reply
timeotter
timeotter Mar. 13 at 9:06 PM
$SXTP been having $EDSA flashback so I'm still holding
0 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

Mar 18, 2026, 8:01 AM EDT - 3 days ago

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

Mar 13, 2026, 9:11 AM EDT - 8 days ago

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

Mar 11, 2026, 7:24 AM EDT - 10 days ago

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Feb 2, 2026, 8:01 AM EST - 6 weeks ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Jan 15, 2026, 8:01 AM EST - 2 months ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 29, 2025, 8:01 AM EST - 2 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Dec 11, 2025, 8:01 AM EST - 3 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 21, 2025, 8:01 AM EST - 4 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Nov 13, 2025, 1:51 PM EST - 4 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 15, 2025, 7:14 AM EDT - 5 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Oct 9, 2025, 7:04 AM EDT - 5 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:02 AM EDT - 7 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 7 months ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 19, 2025, 8:54 AM EDT - 7 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Aug 13, 2025, 4:14 PM EDT - 7 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 16, 2025, 4:01 PM EDT - 8 months ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 8 months ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 15, 2025, 7:01 AM EDT - 8 months ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 10 months ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 10 months ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 11 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 11 months ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 1 year ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 1 year ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Sep 12, 2024, 7:19 AM EDT - 1 year ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 1 year ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jul 9, 2024, 6:31 AM EDT - 1 year ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Jun 27, 2024, 7:59 AM EDT - 1 year ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 30, 2024, 7:59 AM EDT - 1 year ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

Goldwave9
Goldwave9 Mar. 21 at 5:17 PM
$SXTP give this a chance and I don't mean in hours or even in days. It's going to make big move but many of you will have moved on out of boredom
1 · Reply
ReversalTrack
ReversalTrack Mar. 20 at 4:38 PM
Something is brewing on ticker JAGU 🚨🚀 One of the most explosive signals is setting up on the daily. Uranium+Rare earth play with news . War changes everything especially energy. ⚛️ Uranium = energy independence + national security Don't sleep on ticker JAGU!! $SXTP $IPW $IBG $SRXH hot also.1
0 · Reply
ReversalTrack
ReversalTrack Mar. 18 at 10:39 PM
JAGU ✅ Starting to get found, massive potential on this! Make sure to put JAGU on your watchlist. Beaten down IPO now starting to reverse/news yesterday. JAGU uranium/rare earth play, hot sector right now, don't miss this gem! JAGU: ✅23M in cash ✅4$ IPO a month ago ✅No dilution filed ✅Positioned in a growing sector ✅Insiders shares are locked 6 months ✅Laguna salada project covers 230 000 hectares $IPW $SXTP $SRXH $GLD . hot.
1 · Reply
DARKP00L
DARKP00L Mar. 18 at 12:11 PM
$SXTP 08:10 on Mar. 18 2026 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification With FDA For Australian Chestnut Extract; Inks Deal To License Florida State University's Ownership Rights To New Capsule Formulation Methods For Australian Chestnut Extract #tradeideas
0 · Reply
Marty4172
Marty4172 Mar. 17 at 2:46 PM
$SXTP Up on crazy low volume today lfg
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 17 at 6:35 AM
$SXTP lost all gains in 3 days.. on low volume
0 · Reply
TheswingLifes
TheswingLifes Mar. 15 at 6:18 PM
$IPM 5m float, no dilution, great revenues, hot theme that is waiting to take off, whats there not to like, going to get sent, don't be left behind. $ISPC $SAFX $SXTP $CXAI Watching for continuation.
1 · Reply
focafoca99
focafoca99 Mar. 14 at 10:51 PM
$SXTP anything tied to H.C. Wainwright usually gets read through a financing lens first, and I dont think this is any different.
0 · Reply
speedom33
speedom33 Mar. 14 at 2:34 PM
$SXTP The SEC filing was about ATM status. The remaining is 565K which is equavalent to 240,000 shares if converted based on 2.39 closed price. The remaining is a update as of March 12 and may be lowered if more shares were sold through ATM on March 13. I think it is almost done.
0 · Reply
timeotter
timeotter Mar. 13 at 9:06 PM
$SXTP been having $EDSA flashback so I'm still holding
0 · Reply
TerryMitchell96
TerryMitchell96 Mar. 13 at 7:15 PM
$SXTP tiny biotech with obvious asymmetry and squeeze risk if buyers start chasing
0 · Reply
KimberleyAnn
KimberleyAnn Mar. 13 at 5:04 PM
$SXTP Added here
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 13 at 3:23 PM
$SXTP bounce of 2.50 support
0 · Reply
TheswingLifes
TheswingLifes Mar. 13 at 1:29 PM
$IPM 5m float, no dilution, great revenues, hot theme that is waiting to take off, this is going to sent, don't be left behind. $ISPC $SAFX $SXTP watching for continuation.
0 · Reply
BobJobb
BobJobb Mar. 13 at 12:59 PM
$SXTP
0 · Reply
StockScanners
StockScanners Mar. 13 at 4:32 AM
$SXTP reached 3.55
0 · Reply
Shorty1010
Shorty1010 Mar. 12 at 10:46 PM
$SXTP HC Wainwright = dilution kings. They don't give room to run
0 · Reply
focafoca99
focafoca99 Mar. 12 at 10:27 PM
$SXTP filed a new agreement with HC Wainwright
0 · Reply
DeezNutz561
DeezNutz561 Mar. 12 at 7:56 PM
$SXTP 15k on the bid $2.9
0 · Reply
DeezNutz561
DeezNutz561 Mar. 12 at 6:19 PM
$SXTP that buy at $2.58
0 · Reply
BillyBarew
BillyBarew Mar. 12 at 6:18 PM
$SXTP 5
0 · Reply
Heavyd1989
Heavyd1989 Mar. 12 at 5:26 PM
$SXTP 60k shares on the bid
0 · Reply